ArticleBrain and behavior2025
Modulatory Effects of Jujuboside A on Amino Acid Neurotransmitter Profiles in Tic Disorder.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Jingxin Zhidong Formula Alleviates Tic Disorder via Modulation of Microglial IKK/NF-κB Signaling and Striatal Neurotransmitter Homeostasis.Brain and behavior · 2026Article
- Amelioration of tic disorder by Jujuboside A via gut microbiota remodeling and intestinal 5-HT signaling.Frontiers in neuroscience · 2026Article
- Modulatory Effects of Jujuboside A on Amino Acid Neurotransmitter Profiles in Tic Disorder.Brain and behavior · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveThis study investigates the impact of jujuboside A (JuA) on the levels of glutamate (Glu) and gamma-aminobutyric acid (GABA) in the extracellular fluid of the caudate putamen (CPu) in a rat model of tic disorder (TD). It also compares the therapeutic effects of JuA alone and in combination with Tiapride on TD.
methodThe Sprague-Dawley (SD) rats were randomly assigned to five distinct groups: the normal group, the model group, the JuA group, the Tiapride group, and the JuA + Tiapride group. The TD rat model was established through the induction method utilizing intraperitoneal injection of iminodipropionitrile (IDPN). Microdialysis technology was utilized to obtain extracellular fluid from the CPu of rats in each group, and high-performance liquid chromatography (HPLC) was employed to ascertain the levels of Glu and GABA. The stereotypical behavior scores of rats in each group were observed and recorded. Immunohistochemistry was utilized to compare the expression levels of glutamate transporter-1(GLT-1) and glutamate/aspartate transporter (GLAST) proteins in the CPu tissue of rats across the different groups.
resultsIn the TD rats, the Glu content in the CPu extracellular fluid was significantly increased, while the GABA content was significantly decreased, accompanied by a notable increase in stereotypical behavior scores. Both JuA and Tiapride reduced the Glu content and increased the GABA content in the CPu extracellular fluid of TD rats, improving stereotypical behaviors. The combination of JuA and Tiapride showed superior effects compared to either treatment alone, potentially related to the upregulation of GLT-1 and GLAST protein expression in the CPu tissue.
conclusionJuA can improve stereotypical behaviors in TD rats by regulating the levels of Glu and GABA in the CPu extracellular fluid, possibly through the upregulation of GLT-1 and GLAST protein expression. The combination of JuA and Tiapride offers enhanced therapeutic effects, providing a new approach for the treatment of TD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.